

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number

WO 2020/030979 A8

(43) International Publication Date  
13 February 2020 (13.02.2020)

WIPO | PCT

## (51) International Patent Classification:

A61P 37/00 (2006.01) C07K 16/00 (2006.01)  
A61K 35/17 (2015.01) C12N 5/0783 (2010.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

## (21) International Application Number:

PCT/IB2019/000907

## Published:

— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

## (22) International Filing Date:

09 August 2019 (09.08.2019)

## (88) Date of publication of the international search report:

09 April 2020 (09.04.2020)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (48) Date of publication of this corrected version:

25 March 2021 (25.03.2021)

## (30) Priority Data:

62/717,234 10 August 2018 (10.08.2018) US

## (15) Information about Correction:

see Notice of 25 March 2021 (25.03.2021)

(71) Applicant: SANGAMO THERAPEUTICS FRANCE  
[FR/FR]; Allée de la Nertière, Les Cardoulines, 06560 Val-  
bonne Sophia Antipolis (FR).

## Previous Correction:

see Notice of 22 May 2020 (22.05.2020)

(72) Inventors: ABEL, Tobias; c/o Sangamo Therapeutics  
France, Allée de la Nertière, Les Cardoulines, 06560  
Valbonne Sophia Antipolis (FR). FENARD, David; c/  
o Sangamo Therapeutics France, Allée de la Nertière,  
Les Cardoulines, 06560 Valbonne Sophia Antipolis (FR).  
GERTNER-DARDENNE, Julie; c/o Sangamo Therapeu-  
tics France, Allée de la Nertière, Les Cardoulines, 06560  
Valbonne Sophia Antipolis (FR). MEYER, François; c/  
o Sangamo Therapeutics France, Allée de la Nertière, Les  
Cardoulines, 06560 Valbonne Sophia Antipolis (FR).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,  
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,  
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,  
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,  
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: NEW CAR CONSTRUCTS COMPRISING TNFR2 DOMAINS

(57) Abstract: The present invention relates to a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof, and to an immune cell expressing said CAR. The present invention further relates to therapeutic methods comprising the administration of an immune cell expressing a chimeric antigen receptor (CAR) comprising a human TNFR2 transmembrane domain (TM) or a fragment or variant thereof and/or a human TNFR2 costimulatory intracellular signaling domain or a fragment or variant thereof.



WO 2020/030979 A8